Table 1 Summary of demographic and treatment data.
From: An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
Sample ID | Karyotype | Gender | Age | Elapsed time (months) | Induction | Maintenance | Pathway |
|---|---|---|---|---|---|---|---|
1305 | 11;14 | Male | 51 | 38.34 | CTD | No | Intensive |
1334 | 11;14 | Female | 43 | 24.00 | CTD | Missing | Intensive |
5834 | 11;14 | Female | 69 | 29.93 | CTDa | No | Nonintensive |
6030 | 4;14 | Female | 36 | 19.75 | CTD | No | Intensive |
6178 | 11;14 | Female | 67 | 18.40 | RCD | Missing | Intensive |
6229 | 11;14 | Male | 74 | 9.23 | CTDa | Missing | Nonintensive |
6706 | 11;14 | Male | 59 | 25.43 | RCD | No | Intensive |
6988 | 11;14 | Male | 69 | 12.26 | RCDa | No | Nonintensive |
7020 | 4;14 | Female | 58 | 14.69 | CTD | Missing | Intensive |
7240 | 4;14 | Male | 55 | 11.30 | RCD | Lenalidomide | Intensive |
7801 | 14;16 | Female | 48 | 14.49 | CTD | Missing | Intensive |
7842 | 4;14 | Male | 66 | 17.64 | CTD | No | Intensive |
8237 | 4;14 | Female | 49 | 14.00 | CTD | No | Intensive |
9126 | 11;14 | Male | 64 | 16.23 | CTDa | Missing | Nonintensive |
9166 | 14;16 | Female | 68 | 27.24 | CCRD | No | Intensive |
9515 | 11;14 | Male | 68 | 26.15 | RCDa | Lenalidomide | Nonintensive |
9721 | 14;16 | Male | 64 | 29.44 | CTD | Lenalidomide | Intensive |
10,068 | 4;14 | Male | 71 | 13.77 | RCDa | Lenalidomide and Vorinostat | Nonintensive |
10,365 | 11;14 | Male | 76 | 9.33 | CTD | Missing | Intensive |
11,506 | 14;16 | Male | 77 | 11.83 | CTDa | Lenalidomide | Nonintensive |
11,668 | 4;14 | Male | 49 | 19.29 | RCDa | Missing | Nonintensive |
11,949 | 11;14 | Male | 76 | 14.65 | CTD | Missing | Intensive |
12,546 | 4;14 | Male | 77 | 30.59 | RCD | Missing | Intensive |
13,029 | 4;14 | Male | 62 | 6.90 | CTD | Missing | Intensive |
5695 | 11;14 | Male | 64 | NA | CTD | No | Intensive |
5699 | 11;14 | Female | 68 | NA | CTD | Missing | Intensive |
5836 | 11;14 | Male | 77 | NA | CTDa | No | Nonintensive |
5939 | 4;14 | Male | 65 | NA | CTD | Missing | Intensive |
6016 | 11;14 | Female | 55 | NA | RCD | Missing | Intensive |
6076 | 4;14 | Male | 72 | NA | RCDa | Lenalidomide | Nonintensive |
6163 | 4;14 | Male | 75 | NA | RCDa | Missing | Nonintensive |
6277 | 11;14 | Male | 56 | NA | RCD | Lenalidomide | Intensive |
6279 | 4;14 | Male | 62 | NA | RCD | Lenalidomide | Intensive |
6345 | 4;14 | Female | 72 | NA | CTDa | Missing | Nonintensive |
6415 | 11;14 | Female | 68 | NA | RCDa | Missing | Nonintensive |
6425 | 4;14 | Male | 67 | NA | RCD | Lenalidomide and Vorinostat | Intensive |
6501 | 11;14 | Female | 51 | NA | RCD | Missing | Intensive |
6702 | 4;14 | Female | 78 | NA | CTDa | Missing | Nonintensive |
7000 | 11;14 | Female | 78 | NA | CTDa | Missing | Nonintensive |
7005 | 4;14 | Male | 74 | NA | CTDa | Missing | Nonintensive |
7164 | 11;14 | Female | 80 | NA | RCDa | Missing | Nonintensive |
7348 | 4;14 | Male | 67 | NA | RCDa | No | Nonintensive |
7729 | 4;14 | Male | 65 | NA | RCD | Lenalidomide and Vorinostat | Intensive |
7794 | 4;14 | Female | 52 | NA | CTD | No | Intensive |
7880 | 4;14 | Female | 82 | NA | RCDa | Missing | Non-intensive |
7915 | 4;14 | Male | 59 | NA | CTD | Lenalidomide and Vorinostat | Intensive |
7925 | 4;14 | Male | 59 | NA | CTD | Missing | Intensive |
7950 | 4;14 | Male | 49 | NA | CTD | Lenalidomide and Vorinostat | Intensive |
7956 | 4;14 | Female | 56 | NA | CTD | Missing | Intensive |
8043 | 4;14 | Female | 81 | NA | CTDa | Missing | Non-intensive |
8245 | 11;14 | Female | 63 | NA | RCD | Lenalidomide | Intensive |
8567 | 11;14 | Female | 66 | NA | RCDa | Lenalidomide and Vorinostat | Nonintensive |
8573 | 4;14/HD | Female | 82 | NA | CTDa | Missing | Nonintensive |
8928 | 4;14 | Male | 52 | NA | CTD | Missing | Intensive |
8979 | 4;14 | Male | 76 | NA | CTDa | Missing | Nonintensive |
9069 | 11;14 | Male | 73 | NA | RCDa | Missing | Non-intensive |
9176 | 11;14 | Male | 78 | NA | RCDa | Missing | Nonintensive |
9210 | 11;14 | Male | 69 | NA | CTD | Missing | Intensive |
9249 | 11;14 | Male | 58 | NA | RCD | Lenalidomide | Intensive |
9289 | 11;14 | Male | 56 | NA | CTD | No | Intensive |
9292 | 4;14 | Female | 74 | NA | CTDa | Missing | Nonintensive |
9337 | 11;14 | Female | 71 | NA | CTDa | Missing | Nonintensive |
9376 | 4;14 | Female | 64 | NA | RCD | Missing | Intensive |
9409 | 11;14 | Male | 73 | NA | CTDa | Missing | Nonintensive |
9524 | 4;14 | Male | 51 | NA | RCDa | Lenalidomide | Nonintensive |
9544 | 11;14 | Male | 67 | NA | RCDa | No | Nonintensive |
9623 | 11;14 | Male | 58 | NA | RCD | Lenalidomide | Intensive |
9718 | 4;14 | Male | 66 | NA | RCDa | No | Nonintensive |
9917 | 11;14 | Male | 76 | NA | CTDa | Missing | Nonintensive |
9931 | 11;14 | Female | 55 | NA | RCD | Missing | Intensive |
10,085 | 11;14 | Female | 59 | NA | CCRD | Lenalidomide | Intensive |
10,212 | 11;14 | Female | 79 | NA | RCDa | Lenalidomide | Nonintensive |
10,597 | 4;14 | Male | 59 | NA | CCRD | No | Intensive |
10,772 | 4;14 | Female | 63 | NA | CCRD | Missing | Intensive |
10,801 | 11;14 | Male | 77 | NA | RCDa | Missing | Nonintensive |
11,029 | 4;14 | Female | 73 | NA | RCDa | Missing | Nonintensive |
11,897 | 4;14 | Male | 58 | NA | CCRD | Lenalidomide | Intensive |
12,101 | 4;14 | Male | 62 | NA | CCRD | Missing | Intensive |
12,227 | 11;14 | Male | 57 | NA | CCRD | No | Intensive |
12,541 | 11;14 | Male | 56 | NA | CTD | Missing | Intensive |
